Fig. 5.

The combination of AR-42 and doxorubicin have synergistic activity in osteosarcoma cells. Dose-response curves for D17 and U2OS cells treated with AR-42 and doxorubicin alone and in combination. The concentrations plotted for the combination are those of doxorubicin. D17 and U2OS cells were treated for 72 h with various concentrations of either AR-42 or doxorubicin alone, or in combination, with a fixed ratio of AR-42 to doxorubicin. Cell viability was assessed by MTT assay. Data presented is the average of triplicate determinations from two independent experiments